Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Yangyin Qingfei Decoction for Radiation Pneumonitis Prevention (YARD-01)

A Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Yangyin Qingfei Decoction in Preventing Radiation Pneumonitis

This prospective, randomized, controlled, open-label phase II clinical study will enroll patients with thoracic malignancies who are scheduled to receive thoracic radiotherapy and whose baseline chest CT/high-resolution CT (HRCT) shows no active pulmonary disease or prior radiation-induced lung injury that could interfere with the assessment of radiation pneumonitis (RP). Eligible patients will be randomized 1:1 to a treatment group or a control group. The control group will receive standard thoracic radiotherapy and routine supportive care; the treatment group will additionally receive oral Yangyin Qingfei Formula concurrently. Patients will be followed for 12 months after radiotherapy to evaluate the formula's efficacy, safety, and potential clinical translational value in preventing RP.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

230

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310000
        • Department of Radiotherapy, The First Affiliated Hospital of Zhejiang Chinese Medical University
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria

  1. Age 18-80 years.
  2. A pathologically or cytologically confirmed thoracic malignancy, including lung cancer, esophageal cancer, thymic tumors, or similar tumors.
  3. Planned thoracic radiotherapy, with lung tissue expected to lie within the radiation field.
  4. No active pulmonary disease or prior radiation-induced lung injury on baseline chest CT/HRCT that could interfere with RP assessment.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  6. Estimated survival of at least 6 months.
  7. Blood counts: absolute neutrophil count >=3.0 x 10^9/L, platelets >=100 x 10^9/L, and hemoglobin >=90 g/L.
  8. Biochemistry: total bilirubin, blood urea nitrogen, and creatinine <=1.5 times the upper limit of normal (ULN); alanine aminotransferase and aspartate aminotransferase <=2 times the ULN.
  9. Ability to eat normally and take a Chinese herbal decoction; voluntary participation and written informed consent.

Exclusion criteria

  1. Baseline chest CT/HRCT showing active pulmonary infection, interstitial lung disease, marked pulmonary fibrosis, immunotherapy-related pneumonitis, tumor-related post-obstructive pneumonia, or another pulmonary condition that could interfere with RP assessment.
  2. Unequivocal tumor progression according to RECIST 1.1, or an investigator's judgment that radiotherapy and follow-up cannot be completed in the near term.
  3. Severe hepatic, renal, cardiovascular, gastrointestinal, or metabolic disease that could affect the safety or efficacy assessment of the study treatment.
  4. Pregnancy or breastfeeding, or a severe psychiatric disorder that prevents cooperation with the study.
  5. Participation in another interventional clinical trial within the previous 3 months.
  6. Regular use of other Chinese herbal medicines, Chinese patent medicines, or antifibrotic drugs specifically intended to prevent RP.
  7. Poor adherence, inability to take the herbal decoction regularly, or inability to complete scheduled follow-up.
  8. Any other condition judged by the investigator to make the patient unsuitable for enrollment.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Yangyin Qingfei Formula plus standard thoracic radiotherapy and routine supportive care

Yangyin Qingfei decoction will contain Tai Zi Shen (Pseudostellariae Radix) 15 g, Mai Dong (Ophiopogonis Radix) 15 g, Tian Dong (Asparagi Radix) 15 g, Nan Sha Shen (Adenophorae Radix) 15 g, Bei Sha Shen (Glehniae Radix) 15 g, Huang Qin (Scutellariae Radix) 15 g, and Jiao Shan Zhi (charred Gardeniae Fructus) 9 g. One daily prescription will be administered in two doses, 200 mL per dose. If grade 1 gastrointestinal discomfort or another adverse reaction judged possibly related to the decoction occurs, the dose may be reduced to 100 mL twice daily and restored to 200 mL twice daily after symptoms resolve. For grade 2 adverse reactions, the decoction may be suspended and symptomatic treatment provided; after recovery to grade 0-1, treatment may be resumed, with or without dose reduction, at the investigator's discretion. If a grade >=3 adverse reaction, a serious adverse event, or clinically significant decoction-related intolerance occurs, decoction treatment should be stopped, with the r

Aktiv komparator: Standard thoracic radiotherapy plus routine supportive care

Standard thoracic radiotherapy plus routine supportive care

The control group will receive standard thoracic radiotherapy and routine supportive care without Yangyin Qingfei decoction. Supportive care includes nutritional support and symptomatic management, such as cough relief, expectoration, relief of wheezing, and anti-infective treatment when necessary. Chemotherapy, targeted therapy, or immunotherapy may be administered during follow-up at the investigator's discretion, under the same principles as in the treatment group. Prophylactic amifostine, nintedanib, or other antifibrotic drugs will not be used routinely, nor will other Chinese herbal medicines, Chinese patent medicines, or health supplements specifically intended to prevent RP be used.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Incidence of grade >=2 RP
Tidsramme: 3 months after radiotherapy completion
3 months after radiotherapy completion

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: chao chen, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

20. november 2026

Primær færdiggørelse (Anslået)

1. juni 2029

Studieafslutning (Anslået)

31. december 2029

Datoer for studieregistrering

Først indsendt

11. november 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2027-KS-133-01
  • 2027117845 (Andet bevillings-/finansieringsnummer: 2027 Annual Zhejiang Provincial Traditional Chinese Medicine Science and Technology Program)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

De-identified individual participant data will not be publicly released. Data may be available from the principal investigator upon reasonable request with a formal data-use agreement

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .